Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  McNamara, Maeve ; Furukawa, Nathan ; Cartwright, Emily J.
• Description:
  Incarcerated persons are infected with hepatitis C virus (HCV) at rates ≈10 times higher than that of the general population in the United States. To achieve national hepatitis C elimination goals, the diagnosis and treatment of hepatitis C in incarcerated persons must be prioritized. In 2022, the Centers for Disease Control and Prevention recommended that all persons receive opt-out HCV screening upon entry into a carceral setting. We review recommendations, treatments, and policy strategies used to promote HCV opt-out universal HCV screening and treatment in incarcerated populations in the United States. Treatment of hepatitis C in carceral settings has increased but varies by jurisdiction and is not sufficient to achieve HCV elimination. Strengthening universal HCV screening and treatment of HCV-infected incarcerated persons is necessary for HCV elimination nationwide.
• Subjects:
  Antiviral Agents Hepacivirus Hepatitis C Humans Mass Screening United States
• Keywords:
  Bacteria Burkholderia Pseudomallei Direct-acting Antivirals Hepatitis C Virus History Incarceration Melioidosis Opt-out Universal Screening Substance Use Treatment Viruses
• Source:
  Emerg Infect Dis. 2024; 30(Suppl 1):S80-S87
• Pubmed ID:
  38561831
• Pubmed Central ID:
  PMC10986823
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Volume:
  30
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:a667ecf907896e7d24899956aae9424d3fe0abefdacf54178a53168197169617
• Download URL:
  https://stacks.cdc.gov/view/cdc/152943/cdc_152943_DS1.pdf
• File Type:
  [PDF - 1.81 MB ]